{"id":"r-fm","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R-FM combines the anti-CD20 monoclonal antibody rituximab with the chemotherapy agents fludarabine (a purine analog) and mitoxantrone (an anthracenedione). Rituximab targets CD20 on B cells to enable antibody-dependent cellular cytotoxicity, while the chemotherapy components provide direct cytotoxic activity. This combination approach is designed to improve response rates in indolent and mantle cell lymphomas.","oneSentence":"R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:52:16.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indolent B-cell lymphomas"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT07180823","phase":"NA","title":"The LungVision Navigational Platform for Preoperative Labeling of Pulmonary Ground Glass Nodules With Fiducial Markers","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-21","conditions":"Lung Cancer","enrollment":5},{"nctId":"NCT06378788","phase":"","title":"Muscle Architecture and Muscle Strength in Fibromyalgia","status":"RECRUITING","sponsor":"Bezmialem Vakif University","startDate":"2024-02-01","conditions":"Fibromyalgia, Sarcopenia, Muscle Weakness","enrollment":30},{"nctId":"NCT05314569","phase":"PHASE1","title":"Cardioprotective Effect of Ketamine-dexmeditomidine Versus Fentanyl-midazolam in Open Heart Surgery in Pediatrics","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-04-15","conditions":"Anesthesia","enrollment":81},{"nctId":"NCT06124352","phase":"","title":"Correlation Between Clinical Measurement Scales for Gross Motor Function","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-05-15","conditions":"Cerebral Palsy","enrollment":50},{"nctId":"NCT05295316","phase":"","title":"Risk Factors of Primary Fibromyalgia","status":"COMPLETED","sponsor":"Studio Osteopatico Busto Arsizio","startDate":"2020-04-12","conditions":"Fibromyalgia","enrollment":94},{"nctId":"NCT02269124","phase":"NA","title":"Use of Amplification in Children With Unilateral Hearing Loss","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2014-10-01","conditions":"Unilateral Hearing Loss","enrollment":37},{"nctId":"NCT02703896","phase":"PHASE4","title":"Prophylaxis for Aspiration of Gastric Contents.","status":"COMPLETED","sponsor":"King Saud University","startDate":"2012-01","conditions":"Pulmonary Aspiration of Gastric Contents","enrollment":1920},{"nctId":"NCT01355939","phase":"","title":"Comparative Effectiveness Multicenter Trial for Adhesion Characteristics of Ventral Hernia Repair Mesh","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-05","conditions":"Ventral Hernia, Adhesions","enrollment":173},{"nctId":"NCT00774826","phase":"PHASE3","title":"Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma","status":"UNKNOWN","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2005-12","conditions":"Follicular Lymphoma","enrollment":534},{"nctId":"NCT00859001","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy","status":"COMPLETED","sponsor":"University of Bologna","startDate":"","conditions":"Follicular Lymphoma","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-FM","genericName":"R-FM","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas. Used for Indolent B-cell lymphomas, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}